Streptozotocin-Treated High Fat Fed Mice: A New Type 2 Diabetes Model Used to Study Canagliflozin-Induced Alterations in Lipids and Lipoproteins

Hormone and Metabolic Research

Volumn 49, Issue 5, 2017, Pages 400-406

  Yu, Tian ^a   Sungelo, Mitchell J ^a   Goldberg, Ira J ^b   Wang, Hong ^a   Eckel, Robert H ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

lipoprotein lipase; lipoproteins; SGLT2 inhibitors; type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; CHOLESTEROL; GLUCOSE; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2; TRIACYLGLYCEROL; LIPID; LIPOPROTEIN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; INSULIN TREATMENT; KIDNEY TUBULE ABSORPTION; LIPID DIET; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TISSUE SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL; WHITE ADIPOSE TISSUE; ANIMAL; ANTIBODY SPECIFICITY; BLOOD; C57BL MOUSE; CARDIAC MUSCLE; DRUG EFFECTS; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; METABOLISM;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CANAGLIFLOZIN; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; HEPARIN; INSULIN; LIPIDS; LIPOPROTEIN LIPASE; LIPOPROTEINS; MALE; MICE, INBRED C57BL; MYOCARDIUM; ORGAN SPECIFICITY; STREPTOZOCIN; TRIGLYCERIDES;

EID: 85017475089     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0042-110934     Document Type: Article

References (29)

1. Lavalle-Gonzalez F J Januszewicz A Davidson J Tong C Qiu R Canovatchel W Meininger G Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial Diabetologia 2013 56 2582 2592
2. Neumiller J J White J R Jr Campbell R K Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus Drugs 2010 70 377 385
3. Cefalu W T Leiter L A Yoon K H Arias P Niskanen L Xie J Balis D A Canovatchel W Meininger G Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial Lancet 2013 382 941 950
4. Schernthaner G Gross J L Rosenstock J Guarisco M Fu M Yee J Kawaguchi M Canovatchel W Meininger G Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial Diabetes Care 2013 36 2508 2515
5. Stenlof K Cefalu W T Kim K A Alba M Usiskin K Tong C Canovatchel W Meininger G Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise Diabetes Obes Metab 2013 15 372 382
6. Yale J F Bakris G Cariou B Yue D David-Neto E Xi L Figueroa K Wajs E Usiskin K Meininger G Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease Diabetes Obes Metab 2013 15 463 473
7. Seino Y Ikeda Y Niemoeller E Watanabe D Takagi H Yabe D Inagaki N Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin+/-Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study Horm Metab Res 2015 47 895 900
8. Cefalu W T Stenlof K Leiter L A Wilding J P Blonde L Polidori D Xie J Sullivan D Usiskin K Canovatchel W Meininger G Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes Diabetologia 2015 58 1183 1187
9. Rosenstock J Vico M Wei L Salsali A List J F Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy Diabetes Care 2012 35 1473 1478
10. Ferrannini E Seman L Seewaldt-Becker E Hantel S Pinnetti S Woerle H J A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes Diabetes Obes Metab 2013 15 721 728
11. Wang H Eckel R H Lipoprotein lipase in the brain and nervous system Ann Rev Nutr 2012 32 147 160
12. Goldberg I J Merkel M Lipoprotein lipase: physiology, biochemistry, and molecular biology Front Biosci 2001 6 D388 D405
13. Renard C B Kramer F Johansson F Lamharzi N Tannock L R von Herrath M G Chait A Bornfeldt K E Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions J Clin Invest 2004 114 659 668
14. Jensen D R Knaub L A Konhilas J P Leinwand L A MacLean P S Eckel R H Increased thermoregulation in cold-exposed transgenic mice overexpressing lipoprotein lipase in skeletal muscle: an avian phenotype? J Lipid Res 2008 49 870 879
15. Belfrage P Vaughan M Simple liquid-liquid partition system for isolation of labeled oleic acid from mixtures with glycerides J Lipid Res 1969 10 341 344
16. Krauss R M Levy R I Fredrickson D S Selective measurement of two lipase activities in postheparin plasma from normal subjects and patients with hyperlipoproteinemia J Cin Invest 1974 54 1107 1124
17. Maahs D M Hokanson J E Wang H Kinney G L Snell-Bergeon J K East A Bergman B C Schauer I E Rewers M Eckel R H Lipoprotein subfraction cholesterol distribution is proatherogenic in women with type 1 diabetes and insulin resistance Diabetes 2010 59 1771 1779
18. Schroeder-Gloeckler J M Rahman S M Janssen R C Qiao L Shao J Roper M Fischer S J Lowe E Orlicky D J McManaman J L Palmer C Gitomer W L Huang W O’Doherty R M Becker T C Klemm D J Jensen D R Pulawa L K Eckel R H Friedman J E CCAAT/enhancer-binding protein beta deletion reduces adiposity, hepatic steatosis, and diabetes in Lepr(db/db) mice J Biol Chem 2007 282 15717 15729
19. King A J The use of animal models in diabetes research Br J Pharmacol 2012 166 877 894
20. Wu S Y Wang G F Liu Z Q Rao J J Lu L Xu W Wu S G Zhang J J Effect of geniposide, a hypoglycemic glucoside, on hepatic regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin Acta Pharmacol Sinica 2009 30 202 208
21. Jang S M Yee S T Choi J Choi M S Do G M Jeon S M Yeo J Kim M J Seo K I Lee M K Ursolic acid enhances the cellular immune system and pancreatic beta-cell function in streptozotocin-induced diabetic mice fed a high-fat diet Int Immunopharmacol 2009 9 113 119
22. Srinivasan K Viswanad B Asrat L Kaul C L Ramarao P Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening Pharmacol Res 2005 52 313 320
23. Kusakabe T Tanioka H Ebihara K Hirata M Miyamoto L Miyanaga F Hige H Aotani D Fujisawa T Masuzaki H Hosoda K Nakao K Beneficial effects of leptin on glycaemic and lipid control in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and a high-fat diet Diabetologia 2009 52 675 683
24. Azrolan N Odaka H Breslow J L Fisher E A Dietary fat elevates hepatic apoA-I production by increasing the fraction of apolipoprotein A-I mRNA in the translating pool J Biol Chem 1995 270 19833 19838
25. Noh H L Okajima K Molkentin J D Homma S Goldberg I J Acute lipoprotein lipase deletion in adult mice leads to dyslipidemia and cardiac dysfunction Am J Physiol Endocrinol Metab 2006 291 E755 E760
26. Yokono M Takasu T Hayashizaki Y Mitsuoka K Kihara R Muramatsu Y Miyoshi S Tahara A Kurosaki E Li Q Tomiyama H Sasamata M Shibasaki M Uchiyama Y SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats Eur J Pharmacol 2014 727 66 74
27. Vatner D F Majumdar S K Kumashiro N Petersen M C Rahimi Y Gattu A K Bears M Camporez J P Cline G W Jurczak M J Samuel V T Shulman G I Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids Proc Natl Acad Sci USA 2015 112 1143 1148
28. Clee S M Zhang H Bissada N Miao L Ehrenborg E Benlian P Shen G X Angel A LeBoeuf R C Hayden M R Relationship between lipoprotein lipase and high density lipoprotein cholesterol in mice: modulation by cholesteryl ester transfer protein and dietary status J Lipid Res 1997 38 2079 2089
29. Patsch J R Gotto A M Jr. Olivercrona T Eisenberg S Formation of high density lipoprotein2-like particles during lipolysis of very low density lipoproteins in vitro Proc Natl Acad Sci USA 1978 75 4519 4523